Jefferies analyst Dennis Ding initiated coverage of Rhythm Pharmaceuticals (RYTM) with a Buy rating and $80 price target
Don't Miss Our New Year's Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RYTM:
- 3 Best Stocks to Buy Now, 12/23/2024, According to Top Analysts
- Rhythm announces FDA approval of Imcivree for patients as young as 2
- Nike downgraded, FedEx upgraded: Wall Street’s top analyst calls
- Rhythm Pharmaceuticals initiated with an Outperform at Oppenheimer
- Rhythm Pharmaceuticals price target raised to $75 from $64 at JMP Securities